TKIs Beyond Second-Line Therapy

Cytoreductive Partial Nephrectomy: Framework for Patient Selection

It’s Clear as Day: HIF Signaling is Driving Force of the Clear Cell Morphology

Impact of Mycobacterial Infections on Outcomes of Patients with Metastatic Renal Cell Carcinoma

What morphology can teach us about renal cell carcinoma clonal evolution

Latest Issue

ROUNDTABLE MONOGRAPH

TKIs Beyond Second-Line Therapy: New Perspectives in Renal Cell Carcinoma Therapeutics

Brian I. Rini, Thomas E. Hutson, Robert A. Figlin

Abstract
This roundtable discussion held on March 10, 2021 explores the potential role of current Tyrosine Kinase Inhibitors (TKIs) in the therapeutic landscape of advanced renal cell carcinoma (aRCC). This discussion also integrates new concepts emerging from phase-3 TIVO-3 trial which demonstrated a robust safety/tolerability portfolio of a novel drug tivozanib as third- or fourth-line therapy..........Show full content
CASE REPORT

Cytoreductive Partial Nephrectomy: Framework for Patient Selection

Kyrollis Attalla, Jatin S. Gandhi, Robert J. Motzer, David Jones, Paul Russo

Abstract
We present a case of a cytoreductive partial nephrectomy in a patient with metastatic disease in the context of a small renal mass and pre-existing chronic kidney disease and describe a framework for patient selection. ...Show full content
REVIEW ARTICLE

It’s Clear as Day: HIF Signaling is Driving Force of the Clear Cell Morphology

Aberrant hypoxia signaling orchestrates metabolic reprogramming in clear cell renal cell carcinoma to support glycogen and lipid accumulation.

Whitney A. Brown, W. Kimryn Rathmell and Zachary A. Bacigalupa

Abstract
In this review we will summarize how glycogen, lipid, and cholesterol metabolism play key roles in ccRCC tumor growth and the therapeutic potential of targeting these pathways.......Show full content
KCJ EDITOR’S MEMO

Robert A. Figlin MD

Novel Drug Combinations Gain Traction Across Therapeutic Landscape
More than a year since the COVID-19 crisis upended the face of health care in the United States, its impact on cancer clinical trials has continuously been seismic....Show full content
KCJ MEDICAL INTELLIGENCE

Newsworthy, late-breaking information from Web-based sources, professional societies, and government agencies ...Show full content
KCJ JOURNAL CLUB

Essential Peer-Reviewed Reading in Kidney Cancer

The peer-reviewed articles summarized in this section were selected by the Editor-in-Chief, Robert A. Figlin, MD, for their timeliness, importance, relevance, and potential impact on clinical practice or translational research ...Show full content
KCJ EDITOR’S MEMO

Impact of COVID-19 On Clinical Trial Accrual & Delayed Diagnosis of Cancer

As we are fast approaching the holiday season this year and beginning of 2021, the status of the pandemic still looms large with no signs of slowing down. The COVID-19 pandemic has disrupted virtually every aspect of cancer care and clinical trials – from adding further risks for cancer patients, to impeding the delivery of cancer therapy, and the continuity of cancer clinical trials. For people living with cancer and even for those who have gone into remission but still require continued care/follow-up testing, the COVID-19 pandemic has posed enormous challenges to cope with new normal. ...Show full content
KCJ REVIEW ARTICLE

Dissecting the role of lymphadenectomy in the management of renal cell carcinoma:past, present, and future

Alain Kaldany, Zev R. Leopold, Juliana E. Kim, Hiren V. Patel, Arnav Srivastava, Alexandra L.Tabakin, Eric A. Singer

Abstract
Lymph node involvement in renal cell carcinoma (RCC) portends a poor prognosis. However, the role of lymph node dissection (LND) at the time of tumor resection is not fully understood. Given the paucity of high-quality evidence supporting or refuting the routine use of LND in RCC, further research is needed to shed light on this important topic........Show full content

Tweets by KidneyCancerJ

KCJ

Vol 18, Issue 4
DECEMBER 2020

Table of contents

Latest Issue

Novel Drug Combinations Gain Traction Across Therapeutic Landscape

Subscription Sign Up

Sign Up

Feel free to choose as many as you like.

Terms of Service *

Terms of Service ^*